Skip to Content

In order to provide our customers with the highest quality and products, we would like to inform you that we will implement a price adjustment as of Tuesday, October 1st 2024 for all our products and services. The discount scheme agreed upon in the contract will still apply and will be adjusted to the latest prices. We count on your cooperation to continue working towards our shared goals – together, we impact life and health with science.

Merck
  • Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Cancer research (2020-03-21)
Koen D Flach, Manikandan Periyasamy, Ajit Jadhav, Dorjbal Dorjsuren, Joseph C Siefert, Theresa E Hickey, Mark Opdam, Hetal Patel, Sander Canisius, David M Wilson, Maria Donaldson Collier, Stefan Prekovic, Marja Nieuwland, Roelof J C Kluin, Alexey V Zakharov, Jelle Wesseling, Lodewyk F A Wessels, Sabine C Linn, Wayne D Tilley, Anton Simeonov, Simak Ali, Wilbert Zwart
ABSTRACT

Estrogen receptor α (ERα) is a key transcriptional regulator in the majority of breast cancers. ERα-positive patients are frequently treated with tamoxifen, but resistance is common. In this study, we refined a previously identified 111-gene outcome prediction-classifier, revealing FEN1 as the strongest determining factor in ERα-positive patient prognostication. FEN1 levels were predictive of outcome in tamoxifen-treated patients, and FEN1 played a causal role in ERα-driven cell growth. FEN1 impacted the transcriptional activity of ERα by facilitating coactivator recruitment to the ERα transcriptional complex. FEN1 blockade induced proteasome-mediated degradation of activated ERα, resulting in loss of ERα-driven gene expression and eradicated tumor cell proliferation. Finally, a high-throughput 465,195 compound screen identified a novel FEN1 inhibitor, which effectively blocked ERα function and inhibited proliferation of tamoxifen-resistant cell lines as well as ex vivo-cultured ERα-positive breast tumors. Collectively, these results provide therapeutic proof of principle for FEN1 blockade in tamoxifen-resistant breast cancer. SIGNIFICANCE: These findings show that pharmacologic inhibition of FEN1, which is predictive of outcome in tamoxifen-treated patients, effectively blocks ERα function and inhibits proliferation of tamoxifen-resistant tumor cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
50 mg
Fulfilment and delivery delayed
100 mg
Fulfilment and delivery delayed
500 mg
Fulfilment and delivery delayed
New, lower price on this item!
1 g
Fulfilment and delivery delayed
New, lower price on this item!
5 g
Fulfilment and delivery delayed
New, lower price on this item!
Sigma-Aldrich
Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301, clone JBW301, Upstate®, from mouse
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting human FEN1
Pricing and availability is not currently available.
Sigma-Aldrich
3,3′-Diaminobenzidine tetrahydrochloride hydrate, ISOPAC®
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-Actin Antibody, clone C4, clone C4, Chemicon®, from mouse
Pricing and availability is not currently available.